Fig. 3. Incidence of endometrial adenocarcinoma and adenoacanthoma and use of conjugated estrogens and medroxyprogesterone in the Southern California Kaiser Foundation Health Plan among women aged >45 years. Open line shows incidence of endometrial adenocarcinoma and adenoacanthoma per 100,000 women; solid line shows number of tablets of conjugated estrogens dispensed per woman; crosshatch line shows number of medroxyprogesterone tablets dispensed per woman. (A similar graph depicting milligrams of conjugated estrogens instead of tablets dispensed appears in: Ziel HK, Finkle WD, Greenland S. Decline in incidence of endometrial cancer following increase in prescriptions for opposed conjugated estrogens in a prepaid health plan. Gynecol Oncol 1998;68:253-5[8].)